Meeting the Challenge of Identifying New Treatments for Type 2-low Neutrophilic Asthma.

Meeting the Challenge of Identifying New Treatments for Type 2-low Neutrophilic Asthma. Chest. 2019 Sep 13;: Authors: Kalchiem-Dekel O, Yao X, Levine SJ Abstract Asthma pathobiology can be broadly classified by endotypes of type 2-high and type 2-low disease, with a significant percentage of asthmatics having a type 2-low endotype that is poorly responsive to the anti-inflammatory actions of corticosteroids. Therapeutic approaches that target mediators of type 2-low asthma with neutrophilic airway inflammation have yet to enter clinical practice. Therefore, an unmet need exists for the development of new treatments for patients with a neutrophilic asthma, especially those with severe disease. A goal-oriented methodology may be utilized to address this problem, which focuses on identifying key mediators driving the type 2-low endotype, followed by the development of targeted treatments that can be administered to patients in whom the pathway is active and mediating disease in a precision medicine approach. Since multiple mediators can potentially promote neutrophilic airway inflammation, bioassays will be needed that identify specific factors that have a causal relationship with disease pathobiology in individual patients. Furthermore, since neutrophils play a key role in host defense, rigorous consideration will need to be given to titrating the reduction in mediators that promote neutrophilic airway inflammation from pathologically ...
Source: Chest - Category: Respiratory Medicine Authors: Tags: Chest Source Type: research